Altimmune
Altimmune develops experimental obesity and liver-disease drugs, placing it in the metabolic pool's first layer, GLP-1 manufacturers, because it makes the core drug molecules rather than selling finished treatments.
Checked against the company's own business description in its latest annual filing.
Latest disclosed
10-Q filed 2026-08-12 · period ending 2026-06-30
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.